erenumab (Aimovig)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8]

Indications

* may be useful when other preventive treatments have failed[4]

* may be useful for non-opioid medication overuse headache in patients with chronic migraine[7]

* safe & effective in preventing migraine with aura[6]

Dosage

  • 70 or 140 mg SQ monthly

Adverse effects

Mechanism of action

Clinical trials

LIBERTY study

  • failure of 2-4 previous migraine prophylaxis treatments
  • 30% of patients achieved 50% reduction in migrain days with erenumab[2]

More general terms

References

  1. ↑ Goadsby PJ, Reuter U, Hallstrom Y et al A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 2017; 377:2123-2132. Nov 30, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29171821 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1705848
  2. ↑ 2.0 2.1 George J Erenumab Reduces Migraine in Hard-to-Treat Patients. But questions about long-term risks remain unanswered. MedPage Today. April 17, 2018 https://www.medpagetoday.com/meetingcoverage/aan/72398
    Reuter U, et al. Efficacy and safety of erenumab in episodic migraine patients with 2-4 prior preventive treatment failures: Results from the Phase 3b LIBERTY study. American Academy of Neurology (AAN) 2018.
  3. ↑ 3.0 3.1 Brauser D. FDA Approves First-in-Class Drug Erenumab (Aimovig) for Migraine Prevention. Medscape - May 17, 2018. https://www.medscape.com/viewarticle/896851
    FDA News Release. May 17, 2018 FDA approves novel preventive treatment for migraine. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm608120.htm
  4. ↑ 4.0 4.1 Reuter U, Goadsby PJ, Lanteri-Minet M et al Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet Oct 22, 2018 Reuter U, Goadsby PJ, Lanteri-Minet M https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32534-0/fulltext
    Charles A A new opportunity after migraine treatment failure? Lancet Oct 22, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30360967 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32606-0/fulltext
  5. ↑ George J New Safety Concern for Migraine Drug? FDA: hypertension seen in some erenumab patients https://www.medpagetoday.com/neurology/migraines/90805
    Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C. Hypertension: A new safety risk for patients treated with erenumab. Headache 2021. Jan 10 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33423274 https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14051
  6. ↑ 6.0 6.1 Whitlock Burton K Erenumab Safe, Effective in Preventing Migraine With Aura. Medscape. December 20, 2021 https://www.medscape.com/viewarticle/965194
  7. ↑ 7.0 7.1 Tepper SJ, Dodick DW, Lanteri-Minet M et al Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial. JAMA Neurol. 2024 Sep 16:e243043. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39283627 PMCID: PMC11406451 Free PMC article. https://jamanetwork.com/journals/jamaneurology/fullarticle/2823594
  8. ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION AIMOVIG <TM> (erenumab-aooe) injection, for subcutaneous use https://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/aimovig/aimovig_pi_hcp_english.ashx
Retrieved from "https://aaushi.info/w/index.php?title=A159284&oldid=1226260"